2024-519618-29-00CompletedPhase 1
A study to test Aumolertinib in European participants with genetically linked advanced Lung Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 14 Aug 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 6 Dec 2024
- Start date
- 8 Apr 2025
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
- Diseases
- Lung cancer
- EU CT number
- 2024-519618-29-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 3
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Multispecialty hospital for active treatment Sveta Sofia EOOD | Sofiya | Bulgaria | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.